GlassScriptPhysician profile
Rohit Dwivedi
NPI 1255398194
$77,272.83
in general payments reported to CMS, 2019-2025
59 companies · $4,553 in 2025
The $4,553 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $8,680 · 2021: $9,918 · 2022: $8,321 · 2023: $4,077 · 2024: $10K · 2025: $4,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $4,347 · Travel and Lodging: $1,923 · Consulting Fee: $1,500 · Education: $7.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,250.00 |
| Food and Beverage | $4,347.09 |
| Travel and Lodging | $1,923.43 |
| Consulting Fee | $1,500.00 |
| Education | $7.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $36,345.64 | 2019-2025 | Strensiq |
| Abbvie INC. | $24,576.23 | 2019-2025 | Synthroid, Creon, Ubrelvy |
| Kyowa Kirin, INC. | $7,118.35 | 2023-2024 | Crysvita |
| Novo Nordisk INC | $1,401.78 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $978.31 | 2019-2024 | Wainua |
| Amgen INC. | $693.71 | 2019-2025 | Tepezza, Evenity, Prolia |
| Abbott Laboratories | $609.14 | 2019-2025 | Proclaim, Octrode |
| Medtronic, INC. | $607.35 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Tandem Diabetes Care, INC. | $558.25 | 2019-2020 | |
| Lilly USA, LLC | $485.13 | 2019-2024 | Jardiance |
| Novo Nordisk As | $375.00 | 2024 | |
| Amneal Pharmaceuticals LLC | $365.42 | 2020-2025 | Unithroid |
| Insulet Corporation | $255.00 | 2021-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $226.20 | 2020-2024 | Recorlev |
| Sanofi-Aventis U.S. LLC | $220.90 | 2020-2023 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Dwivedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.